Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Deferred Tax Liability (2016 - 2025)

China Pharma Holdings' Non-Current Deferred Tax Liability history spans 16 years, with the latest figure at $747805.0 for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability rose 2.27% year-over-year to $747805.0; the TTM value through Dec 2025 reached $747805.0, up 2.27%, while the annual FY2025 figure was $747805.0, 2.27% up from the prior year.
  • Non-Current Deferred Tax Liability reached $747805.0 in Q4 2025 per CPHI's latest filing, up from $739733.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $827978.0 in Q1 2022 to a low of $727417.0 in Q2 2023.
  • Average Non-Current Deferred Tax Liability over 5 years is $761736.2, with a median of $744959.5 recorded in 2023.
  • Peak YoY movement for Non-Current Deferred Tax Liability: grew 9.59% in 2021, then dropped 8.65% in 2022.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $824407.0 in 2021, then decreased by 8.46% to $754698.0 in 2022, then dropped by 1.67% to $742114.0 in 2023, then decreased by 1.47% to $731202.0 in 2024, then rose by 2.27% to $747805.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Non-Current Deferred Tax Liability are $747805.0 (Q4 2025), $739733.0 (Q3 2025), and $734246.0 (Q2 2025).